<DOC>
	<DOCNO>NCT01850108</DOCNO>
	<brief_summary>Allogeneic blood marrow transplantation ( alloBMT ) curative therapy variety hematologic disorder , include sickle cell disease thalassemia . Even clear alloBMT give patient improvement disease , myeloablative transplant important toxicity mortality associate . The lack suitable donor continue limit access transplantation . Substantial progress make recently development pre-treatment regimen facilitate sustain engraftment donor marrow reduce toxicity . Most regimens incorporate highly immunosuppressive drug , allow reduction elimination myeloablative agent total body irradiation without endanger sustained engraftment HLA-identical allogeneic stem cell . Preliminary result non-myeloablative allogeneic stem cell transplantation suggest procedure perform patient ineligible myeloablative alloBMT , sustain remission several hematologic malignancy obtain .</brief_summary>
	<brief_title>Non-Myeloablative Conditioning Bone Marrow Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients ineligible BMT HLAmatched sibling donor proceed haploBMT . Patients HLAmatched related donor proceed match BMT . Age 270 year Good performance status ( ECOG 0 1 ; Karnofsky Lansky 70100 ) Patients donor must able sign consent form . First degree relative willing donate Patients must geographically accessible willing participate stage treatment . Eligible diagnosis : Patients sickle cell anemia sickle cell anemia ( Hb SS ) , Hb Sβ° thalassemia , Hb Sβ+ thalassemia , Hb SC disease , Hb SE disease , Hb SD disease , Hemoglobin SO Arab disease HbS hereditary persistence fetal hemoglobin . Other significant hemoglobinopathy also fulfill criterion . Plus one following : 1 . Stroke central nervous system event last 24 hour . 2 . MRI change indicative brain parenchyma damage . 3 . MRA evidence cerebrovascular disease . 4 . Acute chest syndrome require exchange transfusion hospitalization . 5 . Recurrent vasoocclusive pain episode hospitalization crisis ( 2/year last 2 year ) . 6 . Stage I II sickle lung disease . 7 . Transfusion dependent thalassemia Poor performance status ( ECOG &gt; 1 ) . Poor cardiac function : leave ventricular ejection fraction &lt; 35 % . Poor pulmonary function : FEV1 FVC &lt; 40 % predict . Pulmonary hypertension moderate severe echocardiographic standard . Poor liver function : direct bilirubin &gt; 3.1 mg/dl HIVpositive Minor ( donor antirecipient ) ABO incompatibility ABO compatible donor available . Prior transfusion donor recipient cause alloimmunization vs. donor cell . Women childbearing potential currently pregnant ( BetaHCG+ ) practice adequate contraception . Patients debilitate medical psychiatric illness would preclude give informed consent receive optimal treatment followup . Criteria donor eligibility Weight ≥ 20kg age ≥ 18 year Donors must meet selection criterion define Foundation Accreditation Hematopoietic Cell Therapy ( FAHCT ) screen per American Association Blood Banks ( AABB ) . ( AABB guideline recipient informed deviation . ) When one donor available , donor low number HLA allele mismatch choose , unless HLA crossmatch incompatibility medical reason select otherwise , case donor selection responsibility PI , consultation immunogenetics laboratory . In case one donor least degree mismatch , donor select base favorable combination ( ) HLA compatibility crossmatch testing ( ii ) ABO compatibility : HLA crossmatching ( order priority ) 1 . Mutually compatible ( crossmatching antibody ) 2 . Recipient noncrossreactive donor , donor crossreactive recipient 3 . Mutually crossreactive ABO compatibility ( order priority ) Compatible Major incompatibility Minor incompatibility Major minor incompatibility Donors select minimize HLA mismatch hostversusgraft direction . Donor must hemoglobin S =/ &lt; ~50 % .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>